A direct-infusion mass spectrometry workflow could reduce the time required to map monoclonal antibody peptides by as much as 100-fold, according to a study.
The method, called RaPiD-mAb-MS, replaces liquid chromatography with automated nanoelectrospray infusion. It combines 96-well plate sample preparation, high-resolution mass spectrometry, and software that automates peptide matching and modification analysis.
Researchers from the University of Wisconsin-Madison, the Morgridge Institute for Research, and several pharmaceutical companies reported that the workflow can process 96 samples in approximately 1.5 to two hours. The mass spectrometry method takes about 60 seconds per sample, with a total sample-to-sample cycle of roughly two minutes. Conventional LC-MS peptide mapping can require considerably longer separations, column equilibration, and blank runs.
Sample preparation involves antibody reduction, alkylation, precipitation, washing, and tryptic digestion within a filter plate. The resulting peptides are transferred to a second plate and infused by an automated nanoelectrospray system into a high-resolution Orbitrap mass spectrometer. Preparation takes approximately four hours.
Across more than 1,500 experiments involving 28 monoclonal antibody sequences, the workflow achieved median sequence coverage of 100 percent and mean coverage of 97.7 percent. In one test, it provided complete coverage for antibodies based on nirsevimab and semorinemab sequences and approximately 95 percent coverage for molecules based on clesrovimab.
The researchers also evaluated the method’s ability to measure attributes relevant to antibody development. RaPiD-mAb-MS detected oxidation, deamidation, glycosylation, terminal modifications, sequence variants, and antibody-drug conjugation sites. Oxidation measurements from forced-degradation studies correlated closely with conventional LC-MS results.
Stable isotope-labeled peptides indicated an average detection limit of approximately 0.7 percent relative abundance, with results ranging from 0.2 to 1.2 percent depending on the peptide. This sensitivity is lower than targeted LC-MS/MS can provide for some low-abundance species.
Removing chromatography presents additional challenges. Deamidated peptides can overlap with their unmodified counterparts, requiring high-resolution targeted MS/MS. Isoaspartate cannot be detected directly because it is isobaric with aspartate, so the researchers added an optional enzymatic labeling step to create a measurable mass shift.
To demonstrate higher-throughput use, the team analyzed 1,152 forced-degradation samples in about 35.5 hours. The resulting data were used to compare formulation conditions and modification patterns across antibodies.
The authors position the method primarily for discovery, formulation screening, and process development. Conventional LC-MS remains important for ultratrace detection and established regulated quality-control workflows. Further method-specific qualification would be required before direct infusion could support regulated testing.
